The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
Status:
Completed
Trial end date:
2015-03-11
Target enrollment:
Participant gender:
Summary
This 24-week study is a safety and efficacy comparison of MK-1293 and Lantus™ in participants
with type 2 diabetes mellitus (T2DM). The primary hypothesis is that after 24 weeks, the mean
change in hemoglobin A1c (A1C) from baseline is non-inferior (with margin of 0.4%) in
participants treated with MK-1293 compared with that in participants treated with Lantus™.